How does the schwann cell lineage form tumors in NF1?

GLIA

Volumn 56, Issue 14, 2008, Pages 1590-1605

  Carroll, Steven L ^a   Ratner, Nancy ^b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Animal model; Neurofibromatosis type 1; Neurofibromin; Stem cell.; Tumor suppressor

Indexed keywords

ANIMAL; CELL LINEAGE; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; METABOLISM; MUTATION; NEUROFIBROMATOSIS; PATHOLOGY; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; REVIEW; SCHWANN CELL; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEUROFIBROMATOSIS 1; PERIPHERAL NERVOUS SYSTEM; SCHWANN CELLS; SIGNAL TRANSDUCTION;

EID: 56749139735     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.20776     Document Type: Article

References (138)

1. Aoki M, Nabeshima K, Koga K, Hamasaki M, Suzumiya J, Tamura K, Iwasaki H. 2007. Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB. Lab Invest 87:767-779.
2. Aquino J, Hjerling-Leffler J, Koltzenburg M, Villar M, Ernfors P. 2006. In vitro and in vivo differentiation of boundary cap neural crest stem cells into mature Schwann cells. Exp Neurol 198:438-449.
3. Atit RA, Mitchell K, Nguyen L, Warshawsky D, Ratner N. 2000. The neurofibromatosis type 1 (Nf1) tumor suppressor is a modifier of carcinogen- induced pigmentation and papilloma formation in C57Bl/6 mice. J Invest Dermatol 114:1093-1100.
4. Badache A, DeVries GH. 1998. Neurofibrosarcoma-derived Schwann cells overexpress platelet-derived growth factor (PDGF) receptors and are induced to proliferate by PDGF BB. J Cell Physiol 177:334-342.
5. Badache A, Muja N, DeVries GH. 1998. Expression of Kit in neurofibromin-deficient human Schwann cells: Role in Schwann cell hyperplasia associated with type 1 neurofibromatosis. Oncogene 17:795-800.
6. Ballester R, Marchuk D, Boguski M, Saulino A, Letcher R, Wigler M, Collins F. 1990. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 63:851-859.
7. Barbarot S, Nicol C, Volteau C, Le Forestier D, N'Guyen JM, Mansat E, Wolkenstein P, Stalder JF. 2007. Cutaneous lesions in neurofibromatosis 1: Confused terminology. Br J Dermatol 157:183-184.
8. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. 1992. Aberrant regulation of ras proteins in tumour cells from type 1 neurofibromatosis patients. Nature 356:713-715.
9. Birindelli S, Perrone F, Oggionni M, Lavarino C, Pasini B, Vergani B, Ranzani GN, Pierotti MA, Pilotti S. 2001. Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest 81:833-844.
10. Boikis SA, Stratakis CA. 2007. Carney complex: The first 20 years. Curr Opin Neurol 19:24-29.
11. Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW, Buchberg AM, Jenkins NA, Parada LF, Copeland NG. 1994. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 8:1019-1029.
12. Carli M, Ferrari A, Mattke A, Zanetti I, Casanova M, Bisogno G, Cecchetto G, Alaggio R, De Sio L, Koscielniak E, Sotti G, Treuner J. 2005. Pediatric malignant peripheral nerve sheath tumor: The Italian and German Soft Tissue Sarcoma Cooperative Group. J Clin Oncol 23:8422-8430.
13. Carroll SL, Stonecypher MS. 2005. Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors. II. The role of dysregulated growth factor signaling. J Neuropathol Exp Neurol 64:1-9.
14. Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, Bronson RT, Jacks T. 1999. Mouse models of tumor development in neurofibromatosis type 1. Science 286:2172-2176.
15. Cohen PR, Rapini RP, Farhood AI. 1993. Expression of the hematopoietic progenitor cell antigen CD34 in vascular and spindle cell tumors. J Cutan Pathol 20:15-20.
16. Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, Johannessen CM, Hollstein PE, MacCollin M, Cichowski K. 2006. A negative feedback signaling network underlies oncogeneinduced senescence. Cancer Cell 10:459-472.
17. D'Angelo I, Welti S, Bonneau F, Scheffzek K. 2006. A novel bipartite phospholipid-binding module in the neurofibromatosis type 1 protein. EMBO Rep 7:174-179.
18. Dasgupta B, Li W, Perry A, Gutmann DH. 2005. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-ras in astrocytes. Cancer Res 65:236-245.
19. DeClue JE, Heffelfinger S, Benvenuto G, Ling B, Li S, Rui W, Vass WC, Viskochil D, Ratner N. 2000. Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest 105:1233-1241.
20. DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC, Lowy DR. 1992. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69:265-273.
21. Demitsu T, Murata S, Kakurai M, Kiyosawa T, Yaoita H. 1998. Malignant schwannoma-derived cells support human skin mast cell survival in vitro. J Dermatol Sci 16:129-134.
22. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. 1986. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 57:2006-2021.
23. Dugoff L, Sujansky E. 1996. Neurofibromatosis type 1 and pregnancy. Am J Med Genet 66:7-10.
24. Easton DF, Ponder MA, Huson SM, Ponder BA. 1993. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): Evidence for modifying genes. Am J Hum Genet 53:305-313.
25. Evans DGR, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. 2002. Malignant peripheral nerve sheath tumors in neurofibromatosis 1. J Med Genet 39:311-314.
26. Ferner RE. 2007. Neurofibromatosis 1 and neurofibromatosis 2: A twenty first century perspective. Lancet Neurol 6:340-351.
27. Ferner RE, Gutmann DH. 2002. International consensus statement on malignant peripheral nerve sheath tumours in neurofibromatosis 1. Cancer Res 62:1573-1577.
28. Ferner RE, O'Doherty MJ. 2002. Neurofibroma and schwannoma. Curr Opin Neurol 15:679-684.
29. Forus A, Weghuis DO, Smeets D, Fodstad O, Myklebost O, van Kessel AG. 1995. Comparative genomic hybridization analysis of human sarcomas. I. Occurrence of genomic imbalances and identification of a novel major amplicon at 1q21-q22 in soft tissue sarcomas. Genes Chromosomes Cancer 14:8-14.
30. Fukuda T, Ichimura E, Shinozaki T, Sano T, Kashiwabara K, Oyama T, Nakajima T, Nakamura T. 1998. Coexpression of HGF and c-Met/ HGF receptor in human bone and soft tissue tumors. Pathol Int 48:757-762.
31. Gitler AD, Zhu Y, Ismat FA, Lu MM, Yamauchi Y, Parada LF, Epstein JA. 2003. Nf1 has an essential role in endothelial cells. Nat Genet 33:75-79.
32. Golubic M, Roudebush M, Dobrowolski S, Wolfman A, Stacey DW. 1992. Catalytic properties, tissue and intracellular distribution of neurofibromin. Oncogene 7:2151-2159.
33. Gutmann DH. 2001. The neurofibromatoses: When less is more. Hum Mol Genet 10:747-755.
34. Hagel C, Zils U, Peiper M, Kluwe L, Gotthard S, Friedrich RE, Zurakowski D, von DA, Mautner VF. 2007. Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. J Neurooncol 82:187-192.
35. Han JW, McCormick F, Macara IG. 1991. Regulation of Ras-GAP and the neurofibromatosis-1 gene product by eicosanoids. Science 252: 576-579.
36. Hawes JJ, Tuskan RG, Reilly KM. 2007. Nf1 expression is dependent on strain background: Implications for tumor suppressor haploinsufficiency studies. Neurogenetics 8:121-130.
37. Hirota S, Nomura S, Asada H, Ito A, Morii E, Kitamura Y. 1993. Possible involvement of c-kit receptor and its ligand in increase of mast cells in neurofibroma tissues. Arch Pathol Lab Med 117:996-999.
38. Holtkamp N, Atallah I, Okuducu A-F, Mucha J, Hartmann C, Mautner VF, Friedrich RE, Mawrin C, von Deimling A. 2007. MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia 9:671-677.
39. Holtkamp N, Okuducu AF, Mucha J, Afanasieva A, Hartmann C, Atallah I, Estevez-Schwarz L, Mawrin C, Friedrich RE, Mautner VF, von Deimling A. 2006. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis 27:664-671.
40. Holtkamp N, Reuss DE, Atallah I, Kuban RJ, Hartmann C, Mautner VF, Frahm S, Friedrich RE, Algermissen B, Pham VA, Prietz S, Rosenbaum T, Estevez-Schwarz L, von Deimling A. 2004. Subclassification of nerve sheath tumors by gene expression profiling. Brain Pathol 14:258-264.
41. Huang YZ, Rangwala F, Fulkerson PC, Ling B, Reed E, Cox AD, Kamholz J, Ratner N. 2004. Role of TC21/R-Ras2 in enhanced migration of neurofibromin-deficient Schwann cells. Oncogene 23: 368-378.
42. Huijbregts RPH, Roth KA, Schmidt RE, Carroll SL. 2003. Hypertrophic neuropathies and malignant peripheral nerve sheath tumors in transgenic mice overexpressing glial growth factor b3 in myelinating Schwann cells. J Neurosci 23:7269-7280.
43. Huson SM, Harper PS, Compston DA. 1988. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 111:1355-1381.
44. Ingram DA, Hiatt K, King AJ, Fisher L, Shivakumar R, Derstine C, Wenning MJ, Diaz B, Travers JB, Hood A, Marshall M, Williams DA, Clapp DW. 2001. Hyperactivation of p21ras and the hematopoieticspecific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro J Exp Med 194:57-69.
45. Ingram DA, Yang FC, Travers JB, Wenning MJ, Hiatt K, New S, Hood A, Shannon K, Williams DA, Clapp DW. 2000. Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp Med 191:181-188.
46. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. 1994. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 7:353-361.
47. Jessen KR, Mirsky R. 2002. Signals that determine Schwann cell identity. J Anat 200:367-376.
48. Jessen KR, Mirsky R. 2005. The origin and development of glial cells in peripheral nerves. Nat Rev Neurosci 6:671-682.
49. Johannessen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, Lynch RC, Rioth MJ, McClatchey A, Ryeom S, Cichowski K. 2008. TORC1 is essential for NF1-associated malignancies. Curr Biol 18:56-62.
50. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. 2005. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 102:8573-8578.
51. Johansson G, Mahller Y, Collins MH, Kim M-O, Nobukuni T, Perentesis JP, Cripe TP, Lane HA, Kozma S, Thomas G, Ratner N. 2008. Effective in vivo targeting of the mTOR pathway in malignant peripheral nerve sheath tumor. Mol Cancer Ther 7:1237-1245.
52. Joseph NM, Mosher JT, Buchstaller J, Snider P, McKeever PE, Lim M, Conway SJ, Parada LF, Zhu Y, Morrison SJ. 2008. The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. Cancer Cell 13:129-140.
53. Joseph NM, Mukouyana Y, Mosher JT, Jaegle M, Crone SA, Dormand EL, Lee K-F, Meijer D, Anderson DJ, Morrison SJ. 2004. Neural crest stem cells undergo multilineage differentiation in developing peripheral nerves to generate endoneurial fibroblasts in addition to Schwann cells. Development 131:5599-5612.
54. Kadono T, Kikuchi K, Nakagawa H, Tamaki K. 2000. Expressions of various growth factors and their receptors in tissues from neurofibroma. Dermatology 201:10-14.
55. Kadono T, Soma Y, Takehara K, Nakagawa H, Ishibashi Y, Kikuchi K. 1994. The growth regulation of neurofibroma cells in neurofibromatosis type-1: Increased responses to PDGF-BB and TGF-b 1. Biochem Biophys Res Commun 198:827-834.
56. Khalaf WF, Yang FC, Chen S, White H, Bessler W, Ingram DA, Clapp DW. 2007. K-ras is critical for modulating multiple c-kit-mediated cellular functions in wild-type and Nf11/2 mast cells. J Immunol 178:2527-2534.
57. Kim HA, Ling B, Ratner N. 1997. Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: Reversion of some phenotypes by an inhibitor of farnesyl protein transferase. Mol Cell Biol 17:862-872.
58. Kim HA, Ratner N, Roberts TM, Stiles CD. 2001. Schwann cell proliferative responses to cAMP and Nf1 are mediated by cyclin D1. J Neurosci 21:1110-1116.
59. Kim HA, Rosenbaum T, Marchionni MA, Ratner N, DeClue JE. 1995. Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes. Oncogene 11:325-335.
60. Kluwe L, Friedrich R, Mautner VF. 1999. Loss of NF1 allele in Schwann cells but not fibroblasts derived from an NF1-associated neurofibroma. Genes Chromosomes Cancer 24:283-285.
61. Kourea HP, Orlow I, Scheithauer BW, Cordon-Cardo C, Woodruff JM. 1999. Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am J Pathol 155:1855-1860.
62. Lakkis MM, Epstein JA. 1998. Neurofibromin modulation of ras activity is required for normal endocardial-mesenchymal transformation in the developing heart. Development 125:4359-4367.
63. Lakkis MM, Golden JA, O'Shea KS, Epstein JA. 1999. Neurofibromin deficiency in mice causes exencephaly and is a modifier for Splotch neural tube defects. Dev Biol 212:80-92.
64. Le LQ, Parada LF. 2007. Tumor microenvironment and neurofibromatosis type 1: Connecting the GAPs. Oncogene 26:4609-4616.
65. Legius E, Dierick H, Wu R, Hall BK, Marynen P, Cassiman JJ, Glover TW. 1994. TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer 10:250-255.
66. Legius E, Marchuk DA, Collins FS, Glover TW. 1993. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet 3:122-125.
67. Ling BC, Wu J, Miller SJ, Monk KR, Shamekh R, Rizvi TA, Decourten-Myers G, Vogel KS, DeClue JE, Ratner N. 2005. Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell 7:65-75.
68. Lothe RA, Karhu R, Mandahl N, Mertens F, Saeter G, Heim S, Boresen-Dale AL, Kallioniemi OP. 1996. Gain of 17q24-qter detected by comparative genomic hybridization in malignant tumors from patients with von Recklinghausen's neurofibromatosis. Cancer Res 56:4778-4781.
69. Lothe RA, Smith-Sorensen B, Hektoen M, Stenwig AE, Mandahl N, Saeter G, Mertens F. 2001. Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors. Genes Chromosomes Cancer 30:202-206.
70. Maertens O, Brems H, Vandesompele J, De Raedt T, Heyns I, Rosenbaum T, De Schepper S, De Paepe A, Mortier G, Janssens S, Speleman F, Legius E, Messiaen L. 2006. Comprehensive NF1 screening on cultured Schwann cells from neurofibromas. Hum Mutat 27:1030-1040.
71. Mantripragada KK, Spurlock G, Kluwe L, Chuzhanova N, Ferner RE, Frayling IM, Dumanski JP, Guha A, Mautner V, Upadhyaya M. 2008. High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clin Cancer Res 14:1015-1024.
72. Maro G, Vermeren M, Voiculescu O, Melton L, Cohen J, Charnay P, Topilko P. 2004. Neural crest boundary cap cells constitute a source of neuronal and glial cells of the PNS. Nat Neurosci 7:930-938.
73. Martin JR, Webster HD. 1973. Mitotic Schwann cells in developing nerve: Their changes in shape, fine structure, and axon relationships. Dev Biol 32:432.
74. Mattingly RR, Kraniak JM, Dilworth JT, Mathieu P, Bealmear B, Nowak JE, Benjamins JA, Tainsky MA, Reiners JJ Jr. 2006. The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines. J Pharm Exp Ther 316:456-465.
75. Mawrin C, Kirches E, Boltze C, Dietzmann K, Roessner A, Schneider-Stock R. 2002. Immunohistochemical and molecular analysis of p53, RB, and PTEN in malignant peripheral nerve sheath tumors. Virchows Arch 440:610-615.
76. McCaughan JA, Holloway SM, Davidson R, Lam WWK. 2007. Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1. J Med Genet 44:463-466.
77. McClatchey AI, Giovannini M. 2005. Membrane organization and tumorigenesis- The NF2 tumor suppressor, Merlin. Genes Dev 19: 2265-2277.
78. Mechtersheimer G, Otano-Joos M, Ohl S, Benner A, Lehnert T, Willeke F, Moller P, Otto HF, Lichter P, Joos S. 1999. Analysis of chromosomal imbalances in sporadic and NF1-associated peripheral nerve sheath tumors by comparative genomic hybridization. Genes Chromosomes Cancer 25:362-369.
79. Menon AG, Anderson KM, Riccardi VM, Chung RY, Whaley JM, Yandell DW, Farmer GE, Freiman RN, Lee JK, Li FP, Barker DF, Ledbetter DH, Kleider A, Martuza RL, Gusella JF, Seizinger BR. 1990. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci USA 87:5435-5439.
80. Mertens F, Dal Cin P, de Wever I, Fletcher CDM, Mandahl N, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, van den Berghe H, Vanni R, Willen H. 2000. Cytogenetic characterization of peripheral nerve sheath tumours: A report of the CHAMP study group. J Pathol 190:31-38.
81. Mertens F, Rydholm A, Bauer HF, Limon J, Nedoszytko B, Szadowska A, Willen H, Heim S, Mitelman F, Mandahl N. 1995. Cytogenetic findings in malignant peripheral nerve sheath tumors. Int J Cancer 61:793-798.
82. Messiaen LM, Callens T, Mortier G, Beysen D, Vandenbroucke I, Van Roy N, Speleman F, De Paepe A. 2000. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 15:541-555.
83. Miller SJ, Rangwala F, Williams J, Ackerman P, Kong S, Jegga AG, Kaiser S, Aronow BJ, Frahm S, Kluwe L, Mautner V, Upadhyaya M, Muir D, Wallace M, Hagen J, Quelle DE, Watson MA, Perry A, Gutmann DH, Ratner N. 2006. Large-scale molecular comparison of human Schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res 66:2584-2591.
84. Monk KR, Wu J, Williams JP, Finney BA, Fitzgerald ME, Filippi M-D, Ratner N. 2008. Mast cells can contribute to axon-glial dissociation and fibrosis in peripheral nerve. Neuron Glia Biol 3:1-12.
85. Morrison SJ, White PM, Zock C, Anderson DJ. 1999. Prospective identification, isolation by flow cytometry, and in vivo self-renewal of multipotent mammalian neural crest stem cells. Cell 96:737-749.
86. Mousley CJ, Tyeryar KR, Ryan MM, Bankaitis VA. 2006. Sec14p-like proteins regulate phosphoinositide homeostasis and intracellular protein and lipid trafficking in yeast. Biochem Soc Trans 34:346-350.
87. Muir D. 1995. Differences in proliferation and invasion by normal, transformed and NF1 Schwann cell cultures are influenced by matrix metalloproteinase expression. Clin Exp Metastasis 13:303-314.
88. Nielsen GP, Stemmer-Rachamimov AO, Ino Y, Moller MB, Rosenberg AE, Louis DN. 1999. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol 155:1879-1884.
89. Ohba Y, Mochizuki N, Yamashita S, Chan AM, Schrader JW, Hattori S, Nagashima K, Matsuda M. 2000. Regulatory proteins of R-Ras, TC21/R-Ras2, and M-Ras/R-Ras3. J Biol Chem 275:20020-20026.
90. Okada T, You L, Giancotti FG. 2007. Shedding light on Merlin's wizardry. Trends Cell Biol 17:222-229.
91. Packer RJ, Gutmann DH, Rubinstein A, Viskochil D, Zimmerman RA, Vezina G, Small J, Korf B. 2002. Plexiform neurofibromas in NF1: Toward biologic-based therapy. Neurology 58:1461-1470.
92. Perry A, Kunz SN, Fuller CE, Banerjee R, Marley EF, Liapis H, Watson MW, Gutmann DH. 2002. Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol 61:702-709.
93. Plaat BE, Molenaar WM, Mastik MF, Hoekstra HJ, te Meerman GJ, van den Berg E. 1999. Computer-assisted cytogenetic analysis of 51 malignant peripheral-nerve-sheath tumours: Sporadic vs. neurofibromatosistype-1-associated malignant schwannomas. Int J Cancer 83:171-178.
94. Rao UN, Sonmez-Alpan E, Michalopoulos GK. 1997. Hepatocyte growth factor and c-MET in benign and malignant peripheral nerve sheath tumors. Hum Pathol 28:1066-1070.
95. Reilly KM, Broman KW, Bronson RT, Tsang S, Loisel DA, Christy ES, Sun Z, Diehl J, Munroe DJ, Tuskan RG. 2006. An imprinted locus epistatically influences Nstr1 and Nstr2 to control resistance to nerve sheath tumors in a neurofibromatosis type 1 mouse model. Cancer Res 66:62-68.
96. Riccardi VM. 1992. Neurofibromatosis: Phenotype, natural history and pathogenesis, 2nd ed. Baltimore: Johns Hopkins University Press.
97. Rutkowski JL, Wu K, Gutmann DH, Boyer PJ, Legius E. 2000. Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. Hum Mol Genet 9:1059-1066.
98. Ryan JJ, Klein KA, Neuberger TJ, Leftwich JA, Westin EH, Kauma S, Fletcher JA, DeVries GH, Huff TJ. 1994. Role for the stem cell factor/ KIT complex in Schwann cell neoplasia and mast cell proliferation associated with neurofibromatosis. J Neurosci Res 37:415-432.
99. Scheithauer BW, Louis DN, Hunter S, Woodruff JM, Antonescu CR. 2007. Neurofibroma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO classification of tumours of the central nervous system. Lyon, France: International Agency for Research on Cancer. pp 156-157.
100. Scheithauer BW, Woodruff JM, Erlandson RA. 1999. Neurofibroma. In: Scheithauer BW, Woodruff JM, Erlandson RA, editors. Tumors of the peripheral nervous system. Washington, D.C.: Armed Forces Institute of Pathology. pp 177-218.
101. Schmidt H, Taubert H, Meye A, Wurl P, Bache M, Bartel F, Holzhausen HJ, Hinze R. 2000. Gains in chromosomes 7, 8q, 15q and 17q are characteristic changes in malignant but not in benign peripheral nerve sheath tumors from patients with von Recklinghausen's disease. Cancer Lett 155:181-190.
102. Schmidt H, Taubert H, Wurl P, Bache M, Bartel F, Holzhausen HJ, Hinze R. 2001. Cytogenetic characterization of six malignant peripheral nerve sheath tumors: Comparison of karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet 128:14-23.
103. Schmidt H, Wurl P, Taubert H, Meye A, Bache M, Holzhausen HJ, Hinze R. 1999. Genomic imbalances of 7p and 17q in malignant peripheral nerve sheath tumors are clinically relevant. Genes Chromosomes Cancer 25:205-211.
104. Serra E, Rosenbaum T, Winner U, Aledo R, Ars E, Estivill X, Lenard H-G, Lazaro C. 2000. Schwann cells harbor the somatic NF1 mutation in neurofibromas: Evidence of two different Schwann cell subpopulations. Hum Mol Genet 9:3055-3064.
105. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88:593-602.
106. Sheela S, Riccardi VM, Ratner N. 1990. Angiogenic and invasive properties of neurofibroma Schwann cells. J Cell Biol 111:645-653.
107. Sherman LS, Atit R, Rosenbaum T, Cox AD, Ratner N. 2000. Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts. J Biol Chem 275:30740-20745.
108. Stemple D, Anderson D. 1993. Lineage diversification of the neural crest: In vitro investigations. Dev Biol 159:12-23.
109. Stevenson DA, Moyer-Mileur LJ, Murray M, Slater H, Sheng X, Carey JC, Dube B, Viskochil DH. 2007. Bone mineral density in children and adolescents with neurofibromatosis type 1. J Pediatr 150:83-88.
110. Stonecypher MS, Byer SJ, Carroll SL. 2005. Activation of the neuregulin-1/erbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors. Oncogene 24:5589-5605.
111. Storlazzi CT, Brekke HR, Mandahl N, Brosjo O, Smeland S, Lothe RA, Mertens F. 2006. Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumors. J Pathol 209:492-500.
112. Su W, Gutmann DH, Perry A, Abounader R, Laterra J, Sherman LS. 2004. CD44-independent hepatocyte growth factor/c-Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro. Glia 45:297-306.
113. Swapp GH, Main RA. 1973. Neurofibromatosis in pregnancy. Br J Dermatol 88:431-435.
114. The I, Hannigan GE, Cowley GS, Reginald S, Zhong Y, Gusella JF, Hariharan IK, Bernards A. 1997. Rescue of a Drosophila NF1 mutant phenotype by protein kinase A. Science 276:791-794.
115. Theos A, Korf BR. 2006. Pathophysiology of neurofibromatosis type 1. Ann Intern Med 144:842-849.
116. Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM. 2005. Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology 65:205-211.
117. Upadhyaya M, Kluwe L, Spurlock G, Monem B, Majounie E, Mantripragada K, Ruggieri M, Chuzhanova N, Evans DG, Ferner R, Thomas N, Guha A, Mautner V. 2008. Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). Hum Mutat 29:74-82.
118. Urich H, Tien RD. 1998. Tumors of the cranial, spinal and peripheral nerve sheaths. In: Bigner DD, McLendon RE, Bruner JM, editors. Russell and Rubinstein's pathology of tumors of the nervous system. New York: Oxford University Press. pp 141-193.
119. Vogel KS, Klesse LJ, Velasco-Miguel S, Meyers K, Rushing EJ, Parada LF. 1999. Mouse tumor model for neurofibromatosis type 1. Science 286:2176-2179.
120. Wallace MR, Rasmussen SA, Lim IT, Bray BA, Zori RT, Muir D. 2000. Culture of cytogenetically abnormal Schwann cells from benign and malignant NF1 tumors. Genes Chromosomes Cancer 27:117-123.
121. Watanabe T, Oda Y, Tamiya S, Masuda K, Tsuneyoshi M. 2001. Malignant peripheral nerve sheath tumour arising within neurofibroma. An immunohistochemical analysis in the comparison between benign and malignant components. J Clin Pathol 54:631-636.
122. Watson MA, Perry A, Tihan T, Prayson RA, Guha A, Bridge J, Ferner R, Gutmann DH. 2004. Gene expression profiling reveals unique molecular subtypes of neurofibromatosis type 1-associated and sporadic malignant peripheral nerve sheath tumors. Brain Pathol 14: 297-303.
123. Webster HD, Martin R, O'Connell MF. 1973. The relationships between interphase Schwann cells and axons before myelination: A quantitative electron microscopic study. Dev Biol 32:401-416.
124. Weiss SW, Nickoloff BJ. 1993. CD-34 is expressed by a distinctive cell population in peripheral nerve, nerve sheath tumors, and related lesions. Am J Surg Pathol 17:1039-1045.
125. Welti S, Fraterman S, D'Angelo I, Wilm M, Scheffzek K. 2007. The sec14 homology module of neurofibromin binds cellular glycerophospholipids: Mass spectrometry and structure of a lipid complex. J Mol Biol 366:551-562.
126. Widemann BC, Salzer WL, Arceci RJ, Blaney SM, Fox E, End D, Gillespie A, Whitcomb P, Palumbo JS, Pitney A, Jayaprakash N, Zannikos P, Balis FM. 2006. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I, plexiform neurofibromas. J Clin Oncol 24:507-516.
127. Wimmer K, Roca X, Beiglbock H, Callens T, Etzler J, Rao AR, Krainer AR, Fonatsch C, Messiaen L. 2007. Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 50 splice-site disruption. Hum Mutat 28:599-612.
128. Wimmer K, Yao S, Claes K, Kehrer-Sawatzki H, Tinschert S, De Raedt T, Legius E, Callens T, Beiglbock H, Maertens O, Messiaen L. 2006. Spectrum of single- and multiexon NF1 copy number changes in a cohort of 1,100 unselected NF1 patients. Genes Chromosomes Cancer 45:265-276.
129. Wu J, Crimmins JT, Monk KR, Williams JP, Fitzgerald ME, Tedesco S, Ratner N. 2006. Perinatal epidermal growth factor receptor blockade prevents peripheral nerve disruption in a mouse model reminiscent of benign World Health Organization grade I neurofibroma. Am J Pathol 168:1686-1696.
130. Wu J, Williams JP, Rizvi TA, Kordich JJ, Witte D, Meijer D, Stemmer-Rachamimov AO, Cancelas JA, Ratner N. 2008. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell 13:105-116.
131. Xu G, O'Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, Dunn D, Stevens J, Gesteland R, White R, Weiss R. 1990a. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 62:599-608.
132. Xu GF, Lin B, Tanaka K, Dunn D, Wood D, Gesteland R, White R, Weiss R, Tamanoi F. 1990b. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 63:835-841.
133. Yang F-C, Chen S, Clegg T, Li X, Morgan T, Estwick SA, Yuan J, Khalaf W, Burgin S, Travers J, Parada LF, Ingram DA, Clapp DW. 2006b. Nf11/2 mast cells induce neurofibroma like phenotypes through secreted TGF-b signaling. Hum Mol Genet 15:2421-2437.
134. Yang FC, Chen S, Robling AG, Yu X, Nebesio TD, Yan J, Morgan T, Li X, Yuan J, Hock J, Ingram DA, Clapp DW. 2006a. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest 116:2880-2891.
135. Yang F-C, Ingram DA, Chen S, Hingtgen CM, Ratner N, Monk KR, Clegg T, White H, Mead L, Wenning MJ, Williams DA, Kapur R, Atkinson SJ, Clapp DW. 2003. Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf11/2 mast cells. J Clin Invest 112:1851-1861.
136. Zheng H, Chang L, Patel N, Yang J, Lowe L, Burns DK, Zhu Y. 2008. Induction of abnormal proliferation by nonmyelinating Schwann cells triggers neurofibroma formation. Cancer Cell 13:117-128.
137. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. 2002. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296:920-922.
138. Zorick T, Syroid D, Brown A, Gridley T, Lemke G. 1999. Krox-20 controls SCIP expression, cell cycle exit and susceptibility to apoptosis in developing myelinating Schwann cells. Development 126:1397-1406.